Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas
To study efficacy and safety of Mitoxantrone HCL Liposome Injection in patients with relapsed cutaneous T cell lymphomasell
Relapsed Cutaneous T Cell Lymphom
DRUG: Mitoxantrone HCL Liposome Injection
Objective response rate (ORR; complete response + partial response [CR + PR]), Up to 6 months
Duration of Response (DOR), Time from the date at which the patient's objective status is first noted to be a CR or PR to the earliest date progression is documented (assessed up to approximately 24 months)|Time to Response (TTR), Time from the date of registration to the date at which the patient's objective status is first noted to be a CR or PR (assessed up to approximately 24 months)|Progression-free survival (PFS), Up to a total of 24 months after first dose or until disease progression, withdrawal from study, or death|Pruritus remission rate, Up to a total of 24 months after first dose or until disease progression, withdrawal from study, or death
To study efficacy and safety of Mitoxantrone HCL Liposome Injection in patients with relapsed cutaneous T cell lymphomasell